Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Atrogi AB currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 3 distinct examiners across 3 distinct art units. This one-to-one ratio between actions, examiners, and art units suggests that each pending matter involves a unique technical focus within the biotechnology sector. The use of 3 distinct art units indicates that the company's innovations are being reviewed in several different specialized groups.
CLARK, AMY LYNN is the busiest examiner for the company, currently managing 1 pending office action. With 3 pending office actions in total, the portfolio is distributed evenly among 3 distinct examiners. This structure ensures that no single examiner or art unit has a dominant role in the company's current prosecution. Consequently, the company must address the specific requirements of 3 distinct examiners and 3 separate art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARK, AMY LYNN | 1 | 39.2% | +31.1% |
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717134 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | CLARK, AMY LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717134 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | CLARK, AMY LYNN | — |
| 18678103 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | BRAUN, MADELINE E | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1624 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717134 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | CLARK, AMY LYNN | 1628 | §103§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18678103 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | BRAUN, MADELINE E | 1624 | §103§112DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18693573 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES AND MEDICAL USES THEREOF | SHTERENGARTS, SAMANTHA L | 1623 | §102 | Non-Final OA | — | Pending | Mar 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAtrogi AB has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Amy Lynn Clark has the most, with 1 of Atrogi AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
